Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations

Human Molecular Genetics

Volumn 17, Issue 13, 2008, Pages 1916-1921

  Benzinou, Michael ^a,b   Chèvre, Jean Claude ^a   Ward, Kirsten J ^a   Lecoeur, Cécile ^a   Dina, Christian ^a   Lobbens, Stephane ^a   Durand, Emmanuelle ^a   Delplanque, Jérome ^a   Horber, Fritz F ^c   Heude, Barbara ^d,e   Balkau, Beverley ^d,e   Borch johnsen, Knut ^f,g   Jørgensen, Torben ^h   Hansen, Torben ^f   Pedersen, Oluf ^f,g   Meyre, David ^a   Froguel, Philippe ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Klinik Lindberg AG   (Switzerland)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSERM   (France)

^f STENO DIABETES CENTER   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; ENDOCANNABINOID RECEPTOR 1;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EUROPEAN UNION; EXON; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OBESITY; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 45749158085     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn089     Document Type: Article

References (28)

1. Hillard, C.J. (2000) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat., 61, 3-18.
2. Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S. et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 112, 423-431.
3. Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G.I., Palmiter, R.D., Sugiura, T. et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822-825.
4. Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.P. and Soubrie, P. (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 284, R345-R353.
5. Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. and Soubrie, P. (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord., 28, 640-648.
6. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Bohme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P. et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401-404.
7. Bari, M., Paradisi, A., Pasquariello, N. and Maccarrone, M. (2005) Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J. Neurosci. Res., 81, 275-283.
8. Soria, G., Mendizabal, V., Tourino, C., Robledo, P., Ledent, C., Parmentier, M., Maldonado, R. and Valverde, O. (2005) Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology, 30, 1670-1680.
9. Pagotto, U., Vicennati, V. and Pasquali, R. (2005) The endocannabinoid system and the treatment of obesity. Ann. Med., 37, 270-275.
10. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. and Rosenstock, J. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. Jama, 295, 761-775.
11. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O. and Rossner, S. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 1389-1397.
12. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D. and Van Gaal, L.F. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 368, 1660-1672.
13. Despres, J.P., Golay, A. and Sjostrom, L. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 353, 2121-2134.
14. Russo, P., Strazzullo, P., Cappuccio, F.P., Tregouet, D.A., Lauria, F., Loguercio, M., Barba, G., Versiero, M. and Siani, A. (2007) Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J. Clin. Endocrinol. Metab., 92, 2382-2386.
15. Peeters, A., Beckers, S., Mertens, I., Van Hul, W. and Van Gaal, L. (2007) The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine, 31 138-141.
16. Aberle, J., Fedderwitz, I., Klages, N., George, E. and Beil, F.U. (2007) Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm. Metab. Res., 39, 395-397.
17. Muller, T.D., Reichwald, K., Wermter, A.K., Bronner, G., Nguyen, T.T., Friedel, S., Koberwitz, K., Engeli, S., Lichtner, P., Meitinger, T. et al. (2007) No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol. Genet. Metab., 90, 429-434.
18. Zhang, P.W., Ishiguro, H., Ohtsuki, T., Hess, J., Carillo, F., Walther, D., Onaivi, E.S., Arinami, T. and Uhl, G.R. (2004) Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry 9, 916-931.
19. Nyholt, D.R. (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet., 74, 765-769.
20. Li, J. and Ji, L. (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity, 95, 221-227.
21. Horvath, T.L. (2006) The unfolding cannabinoid story on energy homeostasis: Central or peripheral site of action? Int. J. Obes. (Lond), 30 (Suppl 1), S30-S32.
22. Horvath, T.L. (2000) Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser., 894, i-xii. 1-253.
23. Lafay, L., Basdevant, A., Charles, M.A., Vray, M., Balkau, B., Borys, J.M., Eschwege, E. and Romon, M. (1997) Determinants and nature of dietary underreporting in a free-living population: The Fleurbaix Laventie Ville Sante (FLVS) Study. Int. J. Obes. Relat. Metab. Disord., 21, 567-573.
24. Jaziri, R., Lobbens, S., Aubert, R., Pean, F., Lahmidi, S., Vaxillaire, M., Porchay, I., Bellili, N., Tichet, J., Balkau, B. et al. (2006) The PPARG Pro 12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: The Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes, 55, 1157-1162.
25. Woolf, B. (1955) On estimating the relation between blood group and disease. Ann. Hum. Genet., 19, 251-253.
26. Agresti, A. (2001) Exact inference for categorical data: Recent advances and continuing controversies. Stat. Med., 20, 2709-2722.
27. Branson, R., Potoczna, N., Kral, J.G., Lentes, K.U., Hoehe, M.R. and Horber, F.F. (2003) Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N. Engl. J. Med., 348, 1096-1103.
28. Dudbridge, F. (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol., 25, 115-121.